TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effective Analgesia Using the 5 S's During Routine Immunizations at 2 and 4 Months
Brief Summary: The purpose of this study is to observe and measure the analgesic effectiveness of the 5 S's (swaddling, side/stomach position, shushing, swinging, and sucking) alone and combined with sucrose, during routine immunizations at 2 and 4 month well child visits.


Options:
A: Arm Label: Reflexology Group; Type: EXPERIMENTAL; Interventions: Other: Foot Reflexology Methods | Arm Label: Acupressure Group; Type: EXPERIMENTAL; Interventions: Other: Acupressure methods | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Grup | Intervention Type: OTHER; Name: Acupressure methods; Assigned to Arm(s): Acupressure Group | Intervention Type: OTHER; Name: Foot Reflexology Methods; Assigned to Arm(s): Reflexology Group | Intervention Type: OTHER; Name: Control Grup; Assigned to Arm(s): Control Group
B: Arm Label: control; Type: N/A; Interventions: N/A | Arm Label: sucrose; Type: N/A; Interventions: N/A | Arm Label: physical intervention; Type: N/A; Interventions: N/A | Arm Label: physical intervention and sucrose; Type: N/A; Interventions: N/A
C: Arm Label: Self-monitoring of BF and intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Self-monitoring of BF and intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-monitoring of BF and intervention; Assigned to Arm(s): Self-monitoring of BF and intervention
D: Arm Label: Breastfeeding; Type: EXPERIMENTAL; Interventions: Other: Breastfeeding | Arm Label: 24% oral sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: 24% oral sucrose | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding | Intervention Type: DRUG; Name: 24% oral sucrose; Assigned to Arm(s): 24% oral sucrose

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
Brief Summary: The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial is a multicenter, randomized, controlled clinical trial of 1400 patients that will include approximately 60 enrolling sites. The study hypotheses are that treatment of hyperglycemic acute ischemic stroke patients with targeted glucose concentration (80mg/dL - 130 mg/dL) will be safe and result in improved 3 month outcome after stroke.


Options:
A: Arm Label: IV insulin drip with target glucose 80 mg/dL - 130 mg/dL; Type: EXPERIMENTAL; Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL | Arm Label: Sub Q insulin to keep glucose less than 180 mg/dL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL | Intervention Type: DRUG; Name: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Assigned to Arm(s): IV insulin drip with target glucose 80 mg/dL - 130 mg/dL | Intervention Type: DRUG; Name: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL; Assigned to Arm(s): Sub Q insulin to keep glucose less than 180 mg/dL
B: Arm Label: Bedtime supplementation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bedtime insulin Aspart (Novolog) | Arm Label: no bedtime supplementation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bedtime insulin Aspart (Novolog); Assigned to Arm(s): Bedtime supplementation
C: Arm Label: Basal Plus Regimen; Type: EXPERIMENTAL; Interventions: Drug: Basal Plus | Arm Label: Basal Bolus; Type: EXPERIMENTAL; Interventions: Drug: Basal Bolus | Arm Label: sliding scale regular insulin (SSRI); Type: ACTIVE_COMPARATOR; Interventions: Drug: sliding scale regular insulin (SSRI) | Intervention Type: DRUG; Name: sliding scale regular insulin (SSRI); Assigned to Arm(s): sliding scale regular insulin (SSRI) | Intervention Type: DRUG; Name: Basal Bolus; Assigned to Arm(s): Basal Bolus | Intervention Type: DRUG; Name: Basal Plus; Assigned to Arm(s): Basal Plus Regimen
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, Drug: Insulin glulisine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Regular insulin | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Regular insulin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Brief Summary: This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or could not tolerate at least one TNF-antagonist medications in the past (specifically, infliximab, adalimumab, or certolizumab pegol).


Options:
A: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Group 2 ustekinumab 130 mg | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg | Intervention Type: DRUG; Name: Group 2 ustekinumab 130 mg; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Group 3: ustekinumab approximately 6 mg/kg; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): 001
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): B
C: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
D: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Brief Summary: This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or could not tolerate at least one TNF-antagonist medications in the past (specifically, infliximab, adalimumab, or certolizumab pegol).


Options:
A: Arm Label: Placebo IV; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: Ustekinumab 130 milligram (mg); Type: EXPERIMENTAL; Interventions: Drug: Group 2 ustekinumab 130 mg | Arm Label: Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): Placebo IV | Intervention Type: DRUG; Name: Group 2 ustekinumab 130 mg; Assigned to Arm(s): Ustekinumab 130 milligram (mg) | Intervention Type: DRUG; Name: Group 3: ustekinumab approximately 6 mg/kg; Assigned to Arm(s): Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)
B: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Group 2 ustekinumab 130 mg | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg | Intervention Type: DRUG; Name: Group 2 ustekinumab 130 mg; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Group 3: ustekinumab approximately 6 mg/kg; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): 001
C: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
D: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q12w | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q8w | Arm Label: 004; Type: EXPERIMENTAL; Interventions: Drug: Placebo IV, Drug: Ustekinumab 90 mg SC q8w | Arm Label: 005; Type: EXPERIMENTAL; Interventions: Drug: Placebo SC, Drug: Ustekinumab 130 mg IV, Drug: Ustekinumab 90 mg SC q12w | Arm Label: 006; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): 001, 005, 006 | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q8w; Assigned to Arm(s): 003, 004 | Intervention Type: DRUG; Name: Ustekinumab 130 mg IV; Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q12w; Assigned to Arm(s): 002, 005

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Brief Summary: This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.


Options:
A: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
B: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Group 2 ustekinumab 130 mg | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg | Intervention Type: DRUG; Name: Group 2 ustekinumab 130 mg; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Group 3: ustekinumab approximately 6 mg/kg; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): 001
C: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q12w | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q8w | Arm Label: 004; Type: EXPERIMENTAL; Interventions: Drug: Placebo IV, Drug: Ustekinumab 90 mg SC q8w | Arm Label: 005; Type: EXPERIMENTAL; Interventions: Drug: Placebo SC, Drug: Ustekinumab 130 mg IV, Drug: Ustekinumab 90 mg SC q12w | Arm Label: 006; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): 001, 005, 006 | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q8w; Assigned to Arm(s): 003, 004 | Intervention Type: DRUG; Name: Ustekinumab 130 mg IV; Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q12w; Assigned to Arm(s): 002, 005
D: Arm Label: Placebo IV; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: Ustekinumab 130 milligram (mg); Type: EXPERIMENTAL; Interventions: Drug: Group 2 ustekinumab 130 mg | Arm Label: Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): Placebo IV | Intervention Type: DRUG; Name: Group 2 ustekinumab 130 mg; Assigned to Arm(s): Ustekinumab 130 milligram (mg) | Intervention Type: DRUG; Name: Group 3: ustekinumab approximately 6 mg/kg; Assigned to Arm(s): Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Brief Summary: This trial will evaluate safety and efficacy of BI 10773 in hypertensive patients with type 2 diabetes. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular complications, assessment of both glucose and blood pressure lowering effects of BI 10773 in hypertensive patients with type 2 diabetes could provide clinically highly relevant, new information for the use of BI 10773


Options:
A: N/A
B: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Glukose-infusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glucose-infusion | Arm Label: Glucose-insulin infusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glucose-insulin infusion | Intervention Type: DRUG; Name: Glucose-infusion; Assigned to Arm(s): Glukose-infusion | Intervention Type: DRUG; Name: Glucose-insulin infusion; Assigned to Arm(s): Glucose-insulin infusion
C: Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glyburide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
D: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: BI 10773 | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene Covered Stents Versus Standard Medical Therapy for Acute Variceal Bleeding in Patients With Advanced Cirrhosis
Brief Summary: The purpose of this study is to determine whether early use of transjugular intrahepatic portosystemic shunt (TIPS) with Polytetrafluoroethylene (PTFE) covered stents is able to prolong the survival in patients with advanced cirrhosis and acute variceal bleeding.


Options:
A: Arm Label: Portacaval shunt; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Portacaval shunt | Arm Label: Sclerotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sclerotherapy | Intervention Type: PROCEDURE; Name: Portacaval shunt; Assigned to Arm(s): Portacaval shunt | Intervention Type: PROCEDURE; Name: Sclerotherapy; Assigned to Arm(s): Sclerotherapy
B: Arm Label: TIPS treatment; Type: EXPERIMENTAL; Interventions: Procedure: TIPS treatment | Arm Label: Medical treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medical treatment | Intervention Type: PROCEDURE; Name: TIPS treatment; Assigned to Arm(s): TIPS treatment | Intervention Type: DRUG; Name: Medical treatment; Assigned to Arm(s): Medical treatment
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B
D: Arm Label: ET+NSBB; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ET+NSBB | Arm Label: TIPS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transjugular intrahepatic portosystemic shunt (TIPS) | Intervention Type: PROCEDURE; Name: Transjugular intrahepatic portosystemic shunt (TIPS); Assigned to Arm(s): TIPS | Intervention Type: PROCEDURE; Name: ET+NSBB; Assigned to Arm(s): ET+NSBB

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction
Brief Summary: This study will determine whether varenicline is safe and helps people to quit smoking through reduction when they are not willing/able to make an abrupt quit attempt.


Options:
A: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
D: Arm Label: Augmented Treatment; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Behavioral Counseling Sessions, Drug: NicodermCQ | Arm Label: Standard Treatment w/ placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Counseling Sessions, Drug: NicodermCQ, Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Augmented Treatment | Intervention Type: BEHAVIORAL; Name: Behavioral Counseling Sessions; Assigned to Arm(s): Augmented Treatment, Standard Treatment w/ placebo | Intervention Type: DRUG; Name: NicodermCQ; Assigned to Arm(s): Augmented Treatment, Standard Treatment w/ placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard Treatment w/ placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction
Brief Summary: This study will determine whether varenicline is safe and helps people to quit smoking through reduction when they are not willing/able to make an abrupt quit attempt.


Options:
A: Arm Label: HIGH NICOTINE; Type: N/A; Interventions: N/A
B: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Swedish snus (smokeless tobacco) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Onico | Intervention Type: OTHER; Name: Swedish snus (smokeless tobacco); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Onico; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction
Brief Summary: This study will determine whether varenicline is safe and helps people to quit smoking through reduction when they are not willing/able to make an abrupt quit attempt.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chantix, Behavioral: Standard Counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Adherence Counseling, Behavioral: Standard Counseling | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Adherence Counseling; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Standard Counseling; Assigned to Arm(s): 1, 2
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
D: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D